Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Schwelm

2 clinical trials in Schwelm, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Schwelm at a glance
2
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Schwelm

Open in trial search

Triple negative breast cancer+4

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer+2

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Other cities in Germany

The busiest research cities in the country

All 515 cities in Germany

Clinical research in Schwelm

What the registry says about research in the country

01 Schwelm
HER2+ early breast cancer
Clinical research in Schwelm is focusing on neoadjuvant therapy for HER2‑positive early breast cancer, evaluating a novel antibody‑drug conjugate against current chemotherapy standards. Safety monitoring of the investigational agent Comparison with standard‑of‑care regimen Measurement of pathological complete response rates Assessment of three‑year distant disease‑free survival Both trials are actively recruiting at a single site, with one investigator overseeing the study to improve outcomes for patients with HER2‑positive disease.
Triple‑negative early breast cancer (low risk)
In this city, researchers are testing personalized neoadjuvant combinations that pair sacituzumab govitecan with immunotherapy for low‑risk triple‑negative early breast cancer. Evaluation of treatment superiority in pathological complete response Goal of achieving >88% three‑year invasive disease‑free survival Safety and tolerability of the combination regimen Exploration of biomarkers guiding therapy selection The study is currently recruiting at the same research center, reflecting a focused effort to expand therapeutic options for triple‑negative breast cancer patients.
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.